Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2943008 | 0.85 | THRB (0.36) | ALDH1A1TSHRDNM1HTR2AHRH1 | |
| SCHEMBL14186875 | 0.85 | — | — | |
| SCHEMBL24837355 | 0.79 | ALDH1A1 (0.38) | ALDH1A1TSHRDNM1HTR2AHRH1 | |
| SCHEMBL7753817 | 0.79 | THRB (0.44) | THRBLMNA | |
| SCHEMBL6227646 | 0.79 | THRB (0.44) | THRBLMNA | |
| SCHEMBL21906463 | 0.77 | ALDH1A1 (0.36) | ALDH1A1TSHRDNM1HTR2AHRH1 | |
| SCHEMBL13009538 | 0.77 | ALDH1A1 (0.36) | ALDH1A1TSHRDNM1HTR2AHRH1 | |
| SCHEMBL14186877 | 0.77 | THRB (0.31) | THRB | |
| SCHEMBL1637494 | 0.77 | THRB (0.31) | THRB | |
| SCHEMBL27804669 | 0.77 | ALDH1A1 (0.36) | ALDH1A1TSHRDNM1HTR2AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114181415-A | Alkaline anion exchange membrane for fuel cell and preparation method thereof | 长春工业大学 | 2022-03-15 | — | — | CN | claimed |
| EP-2245132-B1 | ENCAPSULATED BENEFIT AGENT | UNILEVER PLC NO 41424 (GB) | 2017-10-18 | — | — | EP | claimed |
| CN-102015993-B | Encapsulated benefit agent | UNILEVER PLC | 2013-03-27 | — | — | CN | claimed |
| EP-2245132-A1 | ENCAPSULATED BENEFIT AGENT | Unilever Plc, A Company Registered In England And Wales under company no. 41424 of Unilever House (GB) | 2010-11-03 | — | — | EP | claimed |
| EP-2118095-B1 | A METHOD FOR THE PREPARATION OF ZOLMITRIPTAN | ZENTIVA KS (CZ) | 2010-11-03 | — | — | EP | claimed |
| US-20100145064-A1 | METHOD FOR THE PREPARATION OF ZOLMITRIPTAN | ZENTIVA K.S. (CZ) | 2010-06-10 | — | — | US | claimed |
| EP-2118095-A1 | A METHOD FOR THE PREPARATION OF ZOLMITRIPTAN | Zentiva, A.S. (CZ) | 2009-11-18 | — | — | EP | claimed |
| WO-2009103576-A1 | ENCAPSULATED BENEFIT AGENT | UNILEVER PLC (GB) | 2009-08-27 | — | — | WO | claimed |
| US-20090062550-A1 | Process for the Large Scale Production of Rizatriptan Benzoate | MATRIX LABORATORIES LTD (IN) | 2009-03-05 | — | — | US | claimed |
| WO-2008104135-A1 | A METHOD FOR THE PREPARATION OF ZOLMITRIPTAN | ZENTIVA, A.S. (CZ) | 2008-09-04 | — | — | WO | claimed |
| EP-1951713-A1 | PROCESS FOR THE LARGE SCALE PRODUCTION OF RIZATRIPTAN BENZOATE | Matrix Laboratories Ltd (IN) | 2008-08-06 | — | — | EP | claimed |
| WO-2008018090-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF ZOLMITRIPTAN | MATRIX LABORATORIES LTD (IN) | 2008-02-14 | — | — | WO | claimed |
| WO-2007054979-A1 | PROCESS FOR THE LARGE SCALE PRODUCTION OF RIZATRIPTAN BENZOATE | MATRIX LABORATORIES LTD (IN) | 2007-05-18 | — | — | WO | claimed |
| US-20070054953-A1 | A NOVEL PROCESS FOR PREPARATION OF INDOLE DERIVATIVES | POTLURI RAMESH B | 2007-03-08 | — | — | US | claimed |
| WO-2006137083-A1 | IMPROVED PROCESS FOR THE PREPARATION OF RIZATRIPTAN BENZOATE | NATCO PHARMA LIMITED (IN) | 2006-12-28 | — | — | WO | claimed |
| CN-122005549-A | Application of indole alkali compound in preparation of medicine or skin care product for treating or preventing skin diseases | 南京效真生物科技有限公司 | 2026-05-12 | — | — | CN | disclosed |
| WO-2026057376-A1 | ALKALINE COMPOSITION, ITS USE AND A PROCESS FOR CLEANING SUBSTRATES COMPRISING COBALT AND COPPER | BASF SE (DE) | 2026-03-19 | — | — | WO | disclosed |
| EP-0240096-A1 | Indole derivatives having a selective vasoconstrictor activity | GLAXO GROUP LIMITED (GB) | 1987-10-07 | — | — | EP | disclosed |
| US-4329439-A | AN ORGANOLITHIUM COMPONENT, AND AN AMINO-ACETAL COMPONENT OF THE CATALYST | THE FIRESTONE TIRE & RUBBER COMPANY (US) | 1982-05-11 | — | — | US | disclosed |
| US-4280927-A | A CHELATE OF HYDROCARBYL LITHIUM AND A DIALKYLAMINOALDEHYDE DIALKYL ACETAL | THE FIRESTONE TIRE & RUBBER COMPANY (US) | 1981-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054953-A1 | A NOVEL PROCESS FOR PREPARATION OF INDOLE DERIVATIVES | INMT, IDO2, IDO1 | ALDH1A1 1282/4885TSHR 3629/4885DNM1 3993/4885 |
| US-20090062550-A1 | Process for the Large Scale Production of Rizatriptan Benzoate | DPP4, HTR3A, SI | ALDH1A1 719/4885TSHR 2576/4885DNM1 3251/4885 |
| US-20100145064-A1 | METHOD FOR THE PREPARATION OF ZOLMITRIPTAN | LPXN, TREH, HTR3A | ALDH1A1 3857/4885TSHR 541/4885DNM1 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.